Methods of distinguishing ischemic stroke from intracerebral hemorrhage

Patent metadata

Field	Value
Publication number	US-11525161-B2
Application number	US-201615572965-A
Country	US
Kind code	B2
Filing date	May 5, 2016
Priority date	May 11, 2015
Publication date	Dec 13, 2022
Grant date	Dec 13, 2022

Abstract

Provided are compositions and methods for differentiating and diagnosing ischemic stroke and subgroups thereof (e.g., cardioembolic stroke, large vessel stroke, atherothrombotic stroke, lacunar stroke) from intracerebral hemorrhage.

First claim

What is claimed is:

1. A solid support comprising a set of oligonucleotide probes, wherein the oligonucleotide probes in the set hybridize under stringent hybridization conditions to different genes and wherein the different genes comprise ZNF33A; FAM35B and RHEBP1; SLAMF1 and UBR4;
wherein the probes are immobilized to the solid support, labeled and greater than 50 nucleotides in length and wherein the solid support comprises probes to no more than 292 genes.

2. A reaction mixture comprising a set of oligonucleotide probes, wherein the oligonucleotide probes in the set hybridize under stringent hybridization conditions to different genes and wherein the different genes comprise ZNF33A; FAM35B and RHEBP1; SLAMF1 and UBR4;
wherein the oligonucleotide probes are greater than 50 nucleotides in length and one or more of the oligonucleotide probes comprise a label comprising a fluorophore, chemiluminescent agent, enzyme or antibody and the mixture comprises probes to no more than 292 genes.

3. The reaction mixture of claim 2 , further comprising one or more oligonucleotide probes that hybridize to one or more exons of one or more genes selected from the group consisting of DUXAP10 and SCP2.

4. A kit comprising a set of oligonucleotide probes, wherein the oligonucleotide probes in the set hybridize under stringent hybridization conditions to different genes and wherein the different genes comprise ZNF33A; FAM35B and RHEBP1; SLAMF1 and UBR4; wherein the oligonucleotide probes are greater than 50 nucleotides in length and one or more of the oligonucleotide probes comprise a label comprising a fluorophore, chemiluminescent agent, enzyme or antibody and the kit comprises probes to no more than 292 genes.

5. The solid support of claim 1 , wherein the solid support is a microarray.

6. The solid support of claim 5 , wherein the microarray is suitable or configured for use in a microfluidic device.

7. The solid support of claim 1 , further comprising one or more oligonucleotide probes that hybridize to one or more exons of one or more genes selected from the group consisting of DUXAP10 and SCP2.

8. A kit comprising the solid support of claim 1 .

9. A kit comprising the reaction mixture of claim 2 .

10. The kit of claim 4 , further comprising one or more oligonucleotide probes that hybridize to one or more exons of one or more genes selected from the group consisting of DUXAP10 and SCP2.

11. The solid support of claim 1 , further comprising one or more oligonucleotide probes that hybridize to one or more genes selected from the group consisting of ODF2L, CENPF, and DAP3.

12. The reaction mixture of claim 2 , further comprising one or more oligonucleotide probes that hybridize to one or more genes selected from the group consisting of ODF2L, CENPF, and DAP3.

13. The kit of claim 4 , further comprising one or more oligonucleotide probes that hybridize to one or more genes selected from the group consisting of ODF2L, CENPF, and DAP3.

Assignees

• Univ California

Inventors

• Stamova-Kiossepacheva Boryana
• Jickling Glen C
• Sharp Frank

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• G01N2800/2871

  Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event · CPC title